Other p53 structure correctors which reached the clinical trials’ testing include COTI-2 [87] or PC14586, a small molecule p53 reactivator that is selective for the p53 Y220C mutation [104], yet these drugs are not being evaluated in MDS or AML patients and therefore will not be discussed in detail in this review. Here, TP53 is linked to acute myeloid leukemia.